For many, the word cancer brings images of hospitals, surgeries, and long, exhausting treatments. But a new drug therapy—dostarlimab—has quietly created a ripple of hope in the cancer world. A hope where the body can recover without harsh surgeries or debilitating therapies.
What exactly is being claimed?
In a recent study published in the New England Journal of Medicine, a group of 103 cancer patients received dostarlimab, an immunotherapy drug, without undergoing any surgery. Surprisingly, 82 patients saw such dramatic tumour shrinkage that surgery was no longer necessary.
In another group of 49 rectal cancer patients, tumours disappeared completely after six months of dostarlimab infusions. No knives. No radiation. Just the immune system, strengthened to do what it does best: fight back.
The truth behind the numbers
It sounds too good to be true—but here's the fine print. These remarkable results came from patients whose tumours had a rare genetic glitch known as a “mismatch repair defect” (MMRd). This flaw makes tumours more vulnerable to the immune system, making them ideal targets for immunotherapy drugs like dostarlimab.
Stories behind the science
Take the case of Maureen Sideris, a 71-year-old woman diagnosed with gastroesophageal junction cancer. Surgery would’ve cost her months of recovery, the ability to eat or lie flat, and possibly her voice for a while. But instead, she entered this experimental program, receiving dostarlimab infusions for nine months. Her tumour disappeared. She didn’t need the surgery.
And she isn’t alone. Of the first rectal cancer patients treated five years ago, all are still disease-free. Two even became mothers—something impossible if they’d gone through traditional therapies.
Why is this more than just a medical win?
Cancer treatments often come with life-altering side effects. Removing a bladder, part of the stomach, or reproductive organs can permanently alter how a person eats, moves, or even starts a family.
This new approach gave back something many cancer survivors never expected to reclaim: normalcy. That’s not just science—it’s deeply human.
Video
Is this the end of cancer surgeries? Not yet
While these results feel like a breakthrough, experts are careful. This was a single-centre study conducted at Memorial Sloan Kettering. Some patients haven’t been followed long enough to say for sure if their cancer might return.
And since many types of cancer were included in the study, each with only a few patients, researchers are urging caution before generalising these results. It’s still early, but incredibly promising.
You may also like
Man Utd boss Ruben Amorim concedes not even Europa League win would save disastrous season
Chris Eubank Sr reveals 'unrecognisable' disguise that got him into son's fight vs Conor Benn
Worst House on the Street hit with same furious complaint minutes into Channel 4 show
Ceat charts out Rs 1,000 cr capex drive for FY26
King Charles reveals big regret over cancer-sufferer Dame Deborah James